News Related to HR+/HER2- Metastatic Breast Cancer

Related coverage linked through entity extraction aliases.

Merck/Gilead Discontinue Lung Cancer Trial as Pfizer, Roivant Report Pipeline Updates

Jun 09, 2026

Merck and Gilead discontinued a Phase 3 lung cancer trial due to lack of statistical significance, while Pfizer initiated a new Phase 1 trial and Roivant Sciences completed enrollment in its Phase 2 PHocus trial for pulmonary hypertension.

Relay Therapeutics Reports Revenue Growth, Narrower Loss, and FDA Breakthrough for Zovegalisib

Mar 03, 2026

Relay Therapeutics reported full-year 2025 revenue of $15.36 million and a narrowed net loss of $276.48 million, while securing FDA Breakthrough Therapy designation for lead asset zovegalisib. The company filed a $96.18 million shelf registration.